Dimeric dipeptide mimetics of BDNF loop 4 are potential antidepressants with novel mechanisms of action

This review covers original research focused on the design, synthesis, and pharmacological evaluation of an innovative dimeric dipeptide mimetic of brain-derived neurotrophic factor (BDNF) loop 4 bis-(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide (GSB-106). Developed using a proprietary appr...

Full description

Saved in:
Bibliographic Details
Main Authors: T. A. Gudasheva, P. Yu. Povarnina, A. V. Tarasyuk, V. P. Zherdev, A. D. Durnev
Format: Article
Language:Russian
Published: LLC “Publisher OKI” 2025-01-01
Series:Фармакокинетика и Фармакодинамика
Subjects:
Online Access:https://www.pharmacokinetica.ru/jour/article/view/433
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review covers original research focused on the design, synthesis, and pharmacological evaluation of an innovative dimeric dipeptide mimetic of brain-derived neurotrophic factor (BDNF) loop 4 bis-(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide (GSB-106). Developed using a proprietary approach for creating low-molecular-weight neurotrophin mimetics, GSB-106 displayed marked antidepressant-like activity following systemic and oral administration. The article details its pharmacological properties in vitro and in vivo, mechanism of action, development of a tablet form of the dipeptide, and findings from toxicological and pharmacokinetic studies.
ISSN:2587-7836
2686-8830